我们重视您的隐私
我们使用 Cookie 分析网站流量并改善您的体验。请参阅我们的隐私政策。
相关临床试验
17
3 进行中
药物批准
0
批准总数
监管机构
监管机构数
成立时间
N/A
进行中（未招募）
1
5.9%
尚未招募
2
11.8%
招募中
9
52.9%
终止
4
23.5%
撤回
暂无批准数据
- SBP Group's subsidiary Chia Tai Tianqing Pharmaceutical has received NDA acceptance from China's CDE for M701, a CD3/EpCAM bispecific antibody targeting malignant ascites. - M701 represents China's first independently developed CD3/EpCAM bispecific antibody, designed to simultaneously target EpCAM on tumor cells and CD3 on immune T cells. - The innovative drug activates T cells to kill tumor cells by forming a bridge between tumor cells and immune T cells through dual-target binding. - This milestone follows several other regulatory achievements for SBP Group, including approvals for naldemedine, culmerciclib, and clinical trial authorization for TQB3205.
